We use cookies to understand how you use our site and to improve the overall user experience. This includes personalizing content and advertising. Read our
Privacy Policy
Profacgen offers CDC Assay Services, providing quantitative, reproducible evaluation of complement-dependent cytotoxicity, enabling precise characterization of classical complement pathway-mediated target cell lysis across therapeutic antibody development workflows.
Complement-dependent cytotoxicity (CDC) is a critical Fc effector mechanism in which the Fc region of an antibody bound to a target cell recruits and activates the C1q complex, triggering the classical complement cascade and culminating in the formation of the membrane attack complex (MAC) and target cell lysis. The ability to measure CDC with physiological relevance, complement source flexibility, and platform adaptability directly supports Fc optimization, biosimilar comparability, mechanism-of-action validation, and regulatory potency testing for complement-activating therapeutic antibodies.
CDC proceeds through a sequential, complement protein-mediated cascade that links antigen recognition on target cells to innate immune-mediated destruction:
Target Cell: Antigen-expressing target cells are identified and bound by the Fab region of the therapeutic antibody, positioning the Fc region for complement recognition
Antibody Binding: Bivalent antibody engagement stabilizes attachment to the target cell surface, with the Fc conformation enabling C1q binding
C1q Recruitment: The C1q subunit of the C1 complex binds to the CH2 domain of the antibody Fc region, initiating the classical complement pathway
Complement Cascade Activation: C1q binding triggers C1r and C1s protease activation, leading to sequential cleavage of C4 and C2, formation of the C3 convertase (C4b2a), and amplification through C3 cleavage and C5 convertase generation
Membrane Attack Complex (MAC): Terminal complement components C5b, C6, C7, C8, and multiple C9 molecules assemble into the MAC, inserting into the target cell membrane
Cell Lysis: MAC formation creates a transmembrane pore, disrupting osmotic integrity and inducing irreversible target cell lysis
Quantitative assessment of each complement activation step—and of the integrated lytic cascade—enables mechanistic understanding, potency determination, and comparability evaluation across antibody candidates, Fc variants, and manufacturing lots.
Our CDC Assay Platforms
Profacgen provides multiple CDC assay platforms to accommodate diverse antibody formats, target cell types, complement sources, and program requirements. Platform selection is guided by desired physiological relevance, complement control, throughput, and analytical resolution.
Human Serum-Based CDC Assays
Physiologically relevant evaluation using human serum as a natural complement source.
Qualified human serum pools with defined complement activity and hemolytic titers
Target cell lysis quantification by viability dyes, LDH release, or flow cytometry
Assessment of CDC under near-physiological complement conditions
Ideal for mechanism-of-action studies, Fc optimization, and clinical relevance evaluation
Complement-Reconstituted CDC Assays
Controlled assay conditions using purified complement components or reconstituted systems.
Purified C1q, C4, C2, C3, and terminal components for defined complement input
Stepwise complement activation assessment and pathway verification
Minimized serum variability and batch-to-batch complement activity fluctuations
Suitable for mechanistic studies, complement component dependency mapping, and standardized potency testing
Cell Viability-Based CDC Assays
High-throughput compatible quantification of complement-mediated target cell death.
Resazurin, MTT, or ATP-based viability assays compatible with 96-well and 384-well formats
Dose-response curve generation for EC50 and relative potency determination
Automated liquid handling and detection for screening campaigns
Optimized for lead candidate ranking, lot release, and comparability studies
Flow Cytometry-Based CDC Assays
Multiparametric analysis of complement activation, deposition, and cell death.
Simultaneous detection of C3b/C4b deposition, MAC formation, and viability markers
Cell population gating for target-specific lysis assessment in mixed cultures
Apoptosis versus necrosis discrimination using annexin V and propidium iodide
Recommended for detailed mechanistic characterization and multiparametric biomarker evaluation
Assay Readouts
Profacgen supports multiple quantitative readouts to capture distinct aspects of CDC biology, enabling comprehensive characterization aligned with program objectives:
Cell Lysis Measurement: Direct quantification of complement-mediated target cell death using viability dyes, LDH release, trypan blue exclusion, or impedance-based systems
Cell Viability: Metabolic activity assessment using resazurin, MTT, or ATP luminescence assays for high-throughput dose-response profiling
Apoptosis/Necrosis: Flow cytometry-based discrimination of early apoptotic (annexin V-positive), late apoptotic, and necrotic (propidium iodide-positive) cell populations
Complement Deposition: Immunofluorescence or flow cytometry detection of C3b, C4b, and iC3b deposition on target cell surfaces as markers of convertase activity
MAC Formation: Quantification of terminal complement complex (C5b-9) insertion into target membranes using specific antibodies or functional pore assays
Complement Biomarker Analysis
Profacgen's CDC assays support detailed complement biomarker analysis to elucidate mechanism, validate pathway activation, and correlate biophysical properties with functional outcomes:
C1q Binding: Direct quantification of C1q recruitment to antibody Fc regions using ELISA, surface plasmon resonance, or cell-based binding assays
C3 Deposition: Assessment of C3 convertase activity and amplification loop engagement through C3b/iC3b detection on target cells or in assay supernatants
C4 Activation: Evaluation of classical pathway initiation through C4a generation and C4b deposition, distinguishing classical from alternative pathway contributions
C5b-9 Detection: Soluble MAC (sC5b-9) quantification in assay supernatants as a surrogate for terminal pathway activation and MAC formation efficiency
Applications
Our CDC assays support a broad spectrum of applications across therapeutic antibody development and characterization:
Anti-CD20 Antibodies: CDC potency assessment for rituximab, obinutuzumab, and next-generation CD20-targeting antibodies where complement activation is a primary mechanism of action
Oncology Antibodies: Evaluation of complement-activating potential for hematological and solid tumor-targeting antibodies, informing indication selection and combination strategies
Fc Optimization: Comparative CDC assessment of Fc-engineered variants designed to enhance or eliminate complement recruitment through modified C1q binding affinity
Biosimilar Development: Rigorous side-by-side comparability testing to demonstrate functional equivalence in CDC activity between innovator and candidate products
Mechanism of Action Studies: Detailed characterization of complement pathway involvement, component dependency, and lytic kinetics to support target biology understanding and regulatory documentation
Deliverables
Profacgen provides structured, decision-ready documentation aligned with your program's analytical and regulatory requirements:
CDC activity curve: Complete concentration-response relationships showing percent lysis or viability across antibody concentrations with replicate data
EC50: Relative potency metrics with 95% confidence intervals, calculated using nonlinear regression (4-parameter logistic or sigmoidal dose-response models)
Complement activation profile: Comprehensive biomarker data including C1q binding, C3/C4 deposition, and C5b-9 generation across assay conditions
Statistical report: Appropriate modeling with goodness-of-fit metrics, replicate precision, outlier evaluation, and equivalence testing for comparability studies
A therapeutic antibody development program targeting CD20-positive malignancies required quantitative CDC data to guide Fc engineering decisions. The objective was to enhance C1q binding and classical complement activation while maintaining favorable pharmacokinetic properties and manufacturability.
Objective:
To generate reproducible, statistically robust CDC potency data across multiple Fc variant candidates using human serum-based and complement-reconstituted assays, enabling identification of variants with optimized complement recruitment.
Approach:
Profacgen implemented a tiered CDC evaluation strategy: human serum-based assays for physiological relevance and complement-reconstituted assays for mechanistic resolution. Dose-response curves were generated for each variant with Ramos or Daudi target cells. Parallel C1q binding assays and C3/C4 deposition analysis were conducted to correlate biophysical complement recruitment with functional lytic potency. Flow cytometry-based multiparametric analysis confirmed MAC formation and cell death mechanisms.
Outcome:
The program identified an Fc variant with significantly enhanced CDC potency relative to wild-type, supported by increased C1q binding, accelerated C3 deposition, and elevated MAC formation. The structured dataset enabled confident progression to in vivo evaluation and regulatory discussion of the optimized lead candidate.
A biosimilar development program required rigorous demonstration of functional equivalence in CDC activity between a candidate anti-CD20 antibody and the reference innovator product. CDC potency was a critical quality attribute for regulatory approval, necessitating a powered comparability study with qualified methods.
Objective:
To execute a statistically powered CDC comparability study demonstrating that the biosimilar candidate falls within the predefined equivalence margin for percent lysis, EC50, and complement biomarker profiles relative to the reference product.
Approach:
Profacgen conducted side-by-side CDC assays using qualified human serum pools and validated target cell lines. Assay qualification included precision, linearity, specificity, and robustness evaluation. Multiple independent runs were performed with appropriate statistical analysis to assess equivalence using two one-sided tests (TOST) and confidence interval approaches. Complement biomarker analysis (C1q binding, C3 deposition, C5b-9) was included to demonstrate mechanistic equivalence.
Outcome:
The biosimilar candidate demonstrated CDC potency, EC50 values, and complement activation profiles within the predefined equivalence margin across all assay conditions and statistical analyses. The comprehensive dataset and structured report supported regulatory submission and accelerated the path to clinical development.
A: CDC (Complement-Dependent Cytotoxicity) is an Fc-mediated immune mechanism in which the antibody Fc region recruits and activates the classical complement cascade, leading to membrane attack complex formation and target cell lysis. ADCC (Antibody-Dependent Cellular Cytotoxicity) involves NK cell-mediated killing through FcγRIIIa engagement. CDC operates through soluble complement proteins, while ADCC requires cellular effector populations.
Q: Which complement source is most appropriate for CDC assays?
A: Human serum provides physiological complement activity and is preferred for mechanism-of-action and clinical relevance studies. However, serum variability requires careful qualification. Complement-reconstituted assays using purified components offer greater control and consistency, making them suitable for standardized potency testing and regulatory comparability studies. Platform selection depends on program objectives and regulatory context.
Q: How does Fc engineering affect CDC potency?
A: Fc engineering can modulate CDC through modifications that enhance or reduce C1q binding. Certain amino acid substitutions in the CH2 domain increase C1q affinity and complement activation. Conversely, aglycosylation or specific mutations can attenuate or silence complement recruitment. Glycan composition also influences C1q binding, with specific glycoforms affecting CDC potency independently of ADCC.
Q: What cell lines are typically used for CDC assays?
A: CDC assay cell line selection depends on target antigen expression and complement regulatory protein profiles. For anti-CD20 antibodies, Ramos, Daudi, and WIL2-S cells are commonly used. Raji cells are frequently employed for anti-CD19 and other hematological targets. Cell lines with high complement regulatory protein expression (CD46, CD55, CD59) may show reduced CDC sensitivity, which should be considered during assay design and target selection.
Q: Can CDC assays support regulatory submissions and lot release?
A: Yes. Profacgen can execute CDC assays under method qualification or validation protocols aligned with ICH Q2(R1) and regulatory expectations for cell-based potency assays. Structured documentation, statistical analysis, and assay performance characterization support IND-enabling studies, BLA submissions, biosimilar comparability packages, and routine lot release testing.
Q: How is complement activity variability controlled across serum sources?
A: For human serum-based assays, we implement serum pool qualification including hemolytic complement titers (CH50), functional activity assessment, and internal reference standards. Multiple serum donors are pooled to reduce individual variability. Complement-reconstituted assays eliminate serum variability entirely by using defined purified components. All platforms include appropriate positive and negative controls to monitor assay performance.
References:
Antibody-based cancer therapy. In: International Review of Cell and Molecular Biology. Vol 331. Elsevier; 2017:289-383. doi:10.1016/bs.ircmb.2016.10.002
Online Inquiry
Fill out this form and one of our experts will respond to you within one business day.
Figure 1. CDC mechanism: antibody binding to target cell, C1q recruitment, complement cascade activation, membrane attack complex (MAC) formation, and target cell lysis. (Hendrikset al., 2017)